Table 3.
Uterotonic drug usage and usage of BCE
| Total cohort (n = 438) | BCE performed (n = 149) | BCE not performed (n = 289) | p value1 | |
|---|---|---|---|---|
| Oxytocin infusion | 432 (98.6%) | 149 (100%) | 283 (97.9%) | 0.10 |
| Ergometrine | 290 (66.2%) | 127 (85.2%) | 163 (56.4%) | < 0.001 |
| Ergometrine-additional dose | 135 (30.8%) | 76 (51.0%) | 59 (20.4%) | < 0.001 |
| Misoprostol | 186 (42.5%) | 93 (62.4%) | 93 (32.2%) | < 0.001 |
| PgF2α | 10 (2.3%) | 8 (5.4%) | 2 (0.7%) | 0.004 |
1Continuous variables were assessed by the t-test and categorical variables were analysed using the chi-squared test. P value of < 0.05 is considered statistically significant